Log in with your email address username.


[Comment] Indian hepatitis C drug patent decision shakes public health community

On May 9, 2016, the Indian Patent Office granted the US pharmaceutical company Gilead a patent for sofosbuvir, a direct-acting antiviral for the treatment of hepatitis C virus (HCV).1 The decision to grant the patent reversed an earlier decision by the Indian Patent Office to reject the application after civil society organisations and generic manufacturers had filed a formal opposition to the patent application.2